Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Articles online first > Minerva Urologica e Nefrologica 2020 Aug 04

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Urologica e Nefrologica 2020 Aug 04

DOI: 10.23736/S0393-2249.20.03808-4

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Radium-223 in mCPRC patients: a large real-life Italian multicenter study

Viviana FRANTELLIZZI 1 , Fabio MONARI 2, Manlio MASCIA 3, Renato P. COSTA 4, Giuseppe RUBINI 5, Angela SPANU 6, Alessio FARCOMENI 7, Elisa LODI RIZZINI 8, Luca CINDOLO 9, Vincenzo TRIPOLI 4, Valentina LAVELLI 5, Susanna NUVOLI 6, Mariano PONTICO 10, Valeria DIONISI 2, Cristina FERRARI 5, Giuseppe DE VINCENTIS 10

1 Department of Molecular Medicine, “Sapienza” University of Rome, Rome, Italy; 2 Radiation Oncology Center, S.Orsola-Malpighi Hospital, Bologna,Italy; 3 Unit of Nuclear Medicine, “Spirito Santo” Hospital, Pescara, Italy; 4 Unit of Nuclear Medicine , Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, Italy; 5 Nuclear Medicine Department, University of Bari "Aldo Moro", Bari, Italy; 6 Unit of Nuclear Medicine, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy; 7 Department of Economics & Finance, University of Rome "Tor Vergata", Rome, Italy; 8 Nuclear Medicine Unit, S.Orsola-Malpighi Hospital, Bologna, Italy; 9 Department of Urology, "Villa Stuart" Private Hospital, Rome, Italy; 10 Department of Radiological Sciences, Oncology and Anatomical Pathology, “Sapienza” University of Rome, Rome, Italy


PDF


BACKGROUND: Radium-223 is a targeted alpha-particles therapy approved for the treatment of mCRPC patients with symptomatic bone metastases. To our knowledge we account for the largest cohort of mCRPC patients subjected to Radium-223 treatment in our country. We aim to describe in a real-life setting the largest cohort of mCRPC patients treated with Radium-223 ever taken into consideration.
METHODS: 430 consecutive mCRPC patients were enrolled. Clinical data have been collected at baseline and at the end of the Radium-223 treatment. Furthermore, the overall survival(OS) of our population has been provided.
RESULTS: 157 patients (36.5%) were still alive at the time of data analysis. A mean number of 4.95±1.6 cycles of Radium-223 was reached by our cohort. 265 patients (61.6%) completed the whole six cycles regimen. The mean follow-up period from the first cycle of Radium-223 to the date of the analysis was 12.7 months. The analysis of patients Annual Incidence Rate (AIR) in relation to the number of Radium-223 cycles received depicting a clear advantage for those patients who completed the whole six administrations planned, with an AIR (AIR=0.32) of much lesser value compared to those that have performed five cycles (AIR =0.98). 165 patients (38.4%) dropped out of treatment for death or disease progression.
CONCLUSIONS: This study offers a cross-section of the clinical performance of Radium-223 treatment in a real-world context, confirming on a large scale the effectiveness of Radium-223 in improving the OS and quality of life, along with the preservation of an excellent safety profile.


KEY WORDS: Radium-223; mCRPC; Prostate cancer; Target alpha Therapy

top of page